Novel Cu(I)-catalyzed one-pot multicomponent synthesis of the antiepileptic drug rufinamide

Novel Cu(I)-catalyzed one-pot multicomponent synthesis of the antiepileptic drug rufinamide NH [Cu(phen)(PPh ) ]NO Br 2 3 2 3 NH NaN , H O, 60 °C, 2 h 3 2 antiepileptic drug Rufinamide (95%) Keywords Rufinamide  2,6-Difluoro benzyl bromide  Green Media  Antiepileptic drug  1,3-Dipolar cycloaddition Electronic supplementary material The online version of this article (doi:10.1007/s11164-017-2906-7) contains supplementary material, which is available to authorized users. & Kaushik Chanda chandakaushik1@gmail.com Department of Chemistry, School of Advanced Sciences, VIT University, Vellore 632014, India 123 4712 D. R. Meena et al. Introduction The disease, epilepsy caused by the chronic neurological disorder of the brain affecting almost people of all ages [1]. According to the World Health Organization (WHO) estimates, out of the 50 million people suffering from different forms of epilepsy worldwide, 80% people is residing in developing countries [2, 3]. The majority of epileptic seizures are controlled by the use of anticonvulsants drugs [4, 5] which are often associated with related side-effects such as blurry vision, fatigue, sleepiness, and stomach upset [6]. In view of the side effects, it is always imperative to develop the new anti epileptic drug (AED). An important example of 1,2,3-triazole ring containing antiepileptic drug is rufinamide developed by Novartis and manufactured by Eisai http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Research on Chemical Intermediates Springer Journals

Novel Cu(I)-catalyzed one-pot multicomponent synthesis of the antiepileptic drug rufinamide

Loading next page...
 
/lp/springer_journal/novel-cu-i-catalyzed-one-pot-multicomponent-synthesis-of-the-y3OnyCH7w2
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media Dordrecht
Subject
Chemistry; Catalysis; Physical Chemistry; Inorganic Chemistry
ISSN
0922-6168
eISSN
1568-5675
D.O.I.
10.1007/s11164-017-2906-7
Publisher site
See Article on Publisher Site

Abstract

NH [Cu(phen)(PPh ) ]NO Br 2 3 2 3 NH NaN , H O, 60 °C, 2 h 3 2 antiepileptic drug Rufinamide (95%) Keywords Rufinamide  2,6-Difluoro benzyl bromide  Green Media  Antiepileptic drug  1,3-Dipolar cycloaddition Electronic supplementary material The online version of this article (doi:10.1007/s11164-017-2906-7) contains supplementary material, which is available to authorized users. & Kaushik Chanda chandakaushik1@gmail.com Department of Chemistry, School of Advanced Sciences, VIT University, Vellore 632014, India 123 4712 D. R. Meena et al. Introduction The disease, epilepsy caused by the chronic neurological disorder of the brain affecting almost people of all ages [1]. According to the World Health Organization (WHO) estimates, out of the 50 million people suffering from different forms of epilepsy worldwide, 80% people is residing in developing countries [2, 3]. The majority of epileptic seizures are controlled by the use of anticonvulsants drugs [4, 5] which are often associated with related side-effects such as blurry vision, fatigue, sleepiness, and stomach upset [6]. In view of the side effects, it is always imperative to develop the new anti epileptic drug (AED). An important example of 1,2,3-triazole ring containing antiepileptic drug is rufinamide developed by Novartis and manufactured by Eisai

Journal

Research on Chemical IntermediatesSpringer Journals

Published: Feb 25, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off